Rising Use of Injectable Weight Loss Drugs in the U.S.
Dobrila Vignjevic/Getty Images/iStockphoto
Impact of Injectable Treatments on Obesity Rates
Recent findings from the Gallup National Health and Well-Being Index reveal a significant rise in the use of injectable medications like Wegovy and Zepbound for weight management. This trend is contributing to a slight reduction in the U.S. obesity rate.
Currently, 37% of American adults are classified as obese, a decrease from the peak of 39.9% observed three years ago.
Popularity of GLP-1 Agonists
The survey highlights a surge in the use of drugs such as semaglutide and tirzepatide, marketed under names like Ozempic, Wegovy, Zepbound, and Mounjaro. The percentage of individuals using these medications has more than doubled, rising from 5.8% in early 2024 to 12.4% recently. These GLP-1 agonists, introduced in 2021, are transforming the approach to obesity by targeting hunger and digestion processes.
Demographic Trends in Medication Use
While the overall decline in obesity is gradual, the most notable reductions are among those aged 40 to 64, who are more likely to use GLP-1 medications. Specifically, individuals aged 50 to 64 have seen a 5-point drop in obesity rates, now at 42.8%. Additionally, women are more likely to use these drugs, experiencing greater weight loss compared to men.
Challenges in Access and Affordability
Despite their effectiveness, access to these medications remains a challenge. Dr. Fatima Cody Stanford from Harvard University points out that insurance coverage is becoming more restrictive. Many insurers plan to cease covering GLP-1 medications next year, potentially leaving patients to pay around $500 monthly out of pocket. Although pharmaceutical companies are developing more affordable pill alternatives, these may still be financially inaccessible for many.
